

Comment on SARS-CoV-2 genome and spike protein, COVID-19, and efficacy of vaccines

Comentario sobre el genoma y la proteína de la espiga del SARS-CoV-2, COVID-19 y la eficacia de las vacunas

Rujittika Mungmunpantipantip^{1*} and Viroj Wiwanitkit^{2,3}

¹Private Academic Consultant, Bangkok, Thailand; ²Chandigarh University, Punjab, India; ³Joesph Ayobabalola University, Ikeji-Arakeji, Nigeria

Dear Editor:

We would like to share ideas on the publication "Importance of the SARS-CoV-2 genome and spike protein in the immunopathogenesis of COVID-19 and in the efficacy of vaccines¹". The SARS-CoV-2 pandemic is currently a significant global health issue, according to Jiménez-Morales et al.¹. According to Jiménez-Morales et al. suggest that the virus's ability to propagate, escape the immune system, and reduce antibody neutralization is due to many mutations in the receptor binding domain (RBD). According to Jiménez-Morales et al., recent research indicates that individuals who have already contracted one variant or subvariant will have a significant likelihood of reacquiring that variant¹. This highlights the importance of developing new vaccines and completely immunizing the global populace.

A number of factors need to be taken into account to fully understand the results. It is impossible to make a connection between asymptomatic COVID-19 and the absence of symptoms without the required laboratory tests. Without extensive laboratory testing, asymptomatic COVID-19 and the lack of clinical symptoms could be incorrectly diagnosed. A silent COVID-19 must be ruled out if neither the most recent clinical signals nor the most recent clinical markers are present². In addition, genetic variations seem to affect how a particular person's immune system responds to COVID-19³. Before the results can be confirmed, more clinical study will be needed.

Funding

The authors declare that they have not received funding.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical considerations

Protection of humans and animals. The authors declare that no experiments involving humans or animals were conducted for this research.

Confidentiality, informed consent, and ethical approval. The study does not involve patient personal data nor requires ethical approval. The SAGER guidelines do not apply.

Declaration on the use of artificial intelligence. The authors declare that no generative artificial intelligence was used in the writing of this manuscript.

References

1. Jiménez-Morales S, Pérez-Amado CJ, Montúfar-Robles I, Fragoso JM, Aranda-Urbe IS, Ramos-Puga DA, et al. Importance of the SARS-CoV-2 genome and spike protein in the immunopathogenesis of COVID-19 and in the efficacy of vaccines. *Cir Cir.* 2023;91:268-76.
2. Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. *J Prev Med Public Health.* 2020;53:70.
3. Čiučulkaitė I, Möhlendick B, Thümmel L, Fisenkci N, Elsner C, Dittmer U, et al. GNB3 c.825c>t polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. *Front Genet.* 2022;13:932043.

*Correspondence:

Rujittika Mungmunpantipantip

E-mail: dramnuaykleebayoon@gmail.com

2444-0507/© 2023 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Date of reception: 22-04-2023

Date of acceptance: 30-05-2023

DOI: 10.24875/CIRUE.M23000823

Cir Cir (Eng). 2025;93(1):124

Contents available at PubMed

www.cirugiaycirujanos.com